# ValenzaBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/valenzabio

- Industry: Biotechnology
- Headquarters: Bethesda, US
- Website: www.valenzabiotech.com
- Total disclosed funding: $79M
- Latest round: Series A (Mar 25, 2021)
- Investors on record: 6

## About

Based in Maryland, US, ValenzaBio, Inc. was founded by co-founders Patrick Crutcher and David Maizenberg. The company is a privately held biopharmaceutical and has raised its first funding in February 2020, followed by Series A funding in April 2021. Also in April 2021, Pierre Fabre Medicament takes an equity stake in the company.

ValenzaBio contains a number of monoclonal antibodies that target surface antigens in order to decrease pathogenic autoreactive cell subpopulations, allowing researchers to develop novel therapeutic options for patients with autoimmune and inflammatory disorders by reducing harmful subpopulations of autoreactive cells. VB119, ValenzaBio's main program, is developed for the treatment of membranous nephropathy (MN), while VB421, for the treatment of thyroid eye disease.

The company generates its revenue by providing treatment options for patients with autoimmune and inflammatory diseases.

The company plans to advance and expand its pipeline towards clinical development, this includes VB119 and VB421.

## Funding rounds

- Series A, Mar 25, 2021, $79M — Fidelity Investments, Pierre Fabre, Ikarian Capital, Janus Henderson Investors, Surveyor Capital, Opaleye Management

## Investors

- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series A
- Pierre Fabre — Series A
- Ikarian Capital — Series A
- Janus Henderson Investors — Series A
- Surveyor Capital — Series A
- Opaleye Management — Series A